MERZ PHARMACEUTICALS GMBH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1908-01-01

Employees: 101

Market Cap: -

Website: https://www.radiesse.de

Clinical Trials

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

Phase 3

Completed

Conditions: Subjective Tinnitus

Interventions: Drug: Neramexane mesylate
Drug: Placebo

First Posted Date: 2009-08-10

Last Posted Date: 2012-11-28

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 455

Registration Number: NCT00955799

Locations: 🇺🇸
Glacier Ear, Nose, and Throat, Head and Neck Surgery, P.C., Kalispell, Montana, United States
🇺🇸
FutureSearch Trials of Dallas, Dallas, Texas, United States
🇺🇸
Wake Research Associates, LLC, Raleigh, North Carolina, United States

and more 71 locations

Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2009-08-10

Last Posted Date: 2011-02-08

Lead Sponsor: Merz Pharmaceuticals GmbH

Registration Number: NCT00955760

Locations: 🇩🇪
AAIPharma Deutschland gmbH & Co. KG, Neu-Ulm, Bayern, Germany

Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane

Phase 1

Completed

Conditions: Healthy Subjects

First Posted Date: 2009-07-09

Last Posted Date: 2011-02-08

Lead Sponsor: Merz Pharmaceuticals GmbH

Registration Number: NCT00936026

Locations: 🇩🇪
AAIPharma Deutschland gmbH & Co. KG, Neu Ulm, Bayern, Germany

Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2009-06-05

Last Posted Date: 2011-05-06

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 36

Registration Number: NCT00915174

Locations: 🇩🇪
AAIharma Deutschland GmbH & Co. KG, Neu Ulm, Bavaria, Germany

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

Phase 3

Terminated

Conditions: Subjective Tinnitus

Interventions: Drug: Neramexane mesylate

First Posted Date: 2009-01-22

Last Posted Date: 2012-11-28

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 821

Registration Number: NCT00827008

Locations: 🇺🇸
Glacier Ear, Nose, and Throat, Head and Neck Surgery, P.C., Kalispell, Montana, United States
🇪🇸
Hospital Sagunto, Sagunto, Valencia, Spain
🇺🇸
Heartland Research Associates, LLC., Wichita, Kansas, United States

and more 131 locations

Memantine and Validation of a New Alzheimer's Disease Scale

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: memantine

First Posted Date: 2008-12-08

Last Posted Date: 2013-02-22

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 487

Registration Number: NCT00804271

Locations: 🇩🇪
University Clinic Gustav Carus, Dresden, Saxony, Germany

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Phase 2

Terminated

Conditions: Nystagmus, Congenital
Nystagmus, Acquired
Multiple Sclerosis

First Posted Date: 2008-12-01

Last Posted Date: 2010-07-01

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 48

Registration Number: NCT00799942

Locations: 🇬🇧
University of Leicester, Leicester Royal Infirmary, Ophthalmology Group, Leicester, United Kingdom

NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines

Phase 3

Completed

Conditions: Glabellar Frown Lines

Interventions: Drug: OnabotulinumtoxinA (Vistabel®)
Drug: NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))

First Posted Date: 2008-10-22

Last Posted Date: 2012-03-08

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 381

Registration Number: NCT00777803

Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders

Phase 2

Withdrawn

Conditions: Sleep-Disordered Breathing

Interventions: Drug: NT 201, a Botulinum neurotoxin type A, free of complexing proteins

First Posted Date: 2008-10-16

Last Posted Date: 2015-03-30

Lead Sponsor: Merz Pharmaceuticals GmbH

Registration Number: NCT00773591

Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

Phase 3

Completed

Conditions: Subjective Tinnitus

Interventions: Drug: Neramexane mesylate
Drug: Placebo

First Posted Date: 2008-10-15

Last Posted Date: 2010-07-01

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 400

Registration Number: NCT00772980

Locations: 🇧🇪
AZ Sint Lucas, ENT department, Gent, Belgium
🇧🇪
University Hospital Brussels, ENT department, Brussels, Belgium
🇧🇪
Clinique Universitaire Saint-Luc, Brussels, Belgium

and more 51 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy